Yuwei Deng1, Lixiong Liu2, Wei Qiang1, Li Hu2, Lei Wang3,4, Zeneng Cheng1. 1. Research Institute of Drug Metabolism and Pharmacokinetics, School of Pharmaceutical Sciences, Central South University, Changsha, 410013, Hunan, China. 2. Department of Rheumatology, Shenzhen People's Hospital, Shenzhen, 518020, Guangdong, China. 3. Research Institute of Drug Metabolism and Pharmacokinetics, School of Pharmaceutical Sciences, Central South University, Changsha, 410013, Hunan, China. wangleivvl@163.com. 4. School of Life Sciences, Central South University, Changsha, 410013, Hunan, China. wangleivvl@163.com.
Abstract
PURPOSE: Although pharmacokinetic (PK) interaction effects of methotrexate (MTX) on adalimumab have been found, the mechanism of these effects is still unclear. In this work, effects of MTX on the concentration of neonatal Fc receptor (FcRn) and the role of FcRn in the interaction between MTX and adalimumab were investigated. METHODS: The experiment was performed in rats whose FcRn had normal physiological function and also in rats whose FcRn was blocked with FcRn antibody. Rats were randomly assigned to receive placebo or 0.2 mg/kg MTX orally every week while taking one abdominal subcutaneous injection of 0.5 mg/kg adalimumab. The FcRn concentration in tissues and the PK parameters of adalimumab were compared between MTX-treated and placebo groups. RESULTS: In rats with normally functioning FcRn, the concentrations of FcRn were significantly increased in the liver (F=105.5, p=0.000) and kidney (F=996.312, p=0.000) after treatment with MTX, and the clearance (CL/F) of adalimumab was decreased accordingly (F=4.423, p=0.048). However, in rats injected with FcRn antibody, the concentrations of FcRn in MTX-treated rats were close to that of the placebo rats in the tissues of the liver (F=1.279, p=0.268) and kidney (F=0.661, p=0.424). The CL/F of adalimumab in rats was also not affected by MTX (F=0.002, p=0.961). CONCLUSIONS: FcRn may play a vital role in the interaction between adalimumab and MTX.
PURPOSE: Although pharmacokinetic (PK) interaction effects of methotrexate (MTX) on adalimumab have been found, the mechanism of these effects is still unclear. In this work, effects of MTX on the concentration of neonatal Fc receptor (FcRn) and the role of FcRn in the interaction between MTX and adalimumab were investigated. METHODS: The experiment was performed in rats whose FcRn had normal physiological function and also in rats whose FcRn was blocked with FcRn antibody. Rats were randomly assigned to receive placebo or 0.2 mg/kg MTX orally every week while taking one abdominal subcutaneous injection of 0.5 mg/kg adalimumab. The FcRn concentration in tissues and the PK parameters of adalimumab were compared between MTX-treated and placebo groups. RESULTS: In rats with normally functioning FcRn, the concentrations of FcRn were significantly increased in the liver (F=105.5, p=0.000) and kidney (F=996.312, p=0.000) after treatment with MTX, and the clearance (CL/F) of adalimumab was decreased accordingly (F=4.423, p=0.048). However, in rats injected with FcRn antibody, the concentrations of FcRn in MTX-treated rats were close to that of the placebo rats in the tissues of the liver (F=1.279, p=0.268) and kidney (F=0.661, p=0.424). The CL/F of adalimumab in rats was also not affected by MTX (F=0.002, p=0.961). CONCLUSIONS:FcRn may play a vital role in the interaction between adalimumab and MTX.
Entities:
Keywords:
adalimumab; drug-drug interaction; methotrexate; neonatal Fc receptor
Authors: Michael E Weinblatt; Edward C Keystone; Daniel E Furst; Larry W Moreland; Michael H Weisman; Charles A Birbara; Leah A Teoh; Steven A Fischkoff; Elliot K Chartash Journal: Arthritis Rheum Date: 2003-01
Authors: Emilie Ducourau; Theo Rispens; Marine Samain; Emmanuelle Dernis; Fabienne Le Guilchard; Lucia Andras; Aleth Perdriger; Eric Lespessailles; Antoine Martin; Grégoire Cormier; Thomas Armingeat; Valérie Devauchelle-Pensec; Elisabeth Gervais; Benoit Le Goff; Annick de Vries; Eric Piver; Gilles Paintaud; Céline Desvignes; David Ternant; Hervé Watier; Philippe Goupille; Denis Mulleman Journal: RMD Open Date: 2020-01-09